CYP4A inhibitor reduced ROS generation, NADPH oxidase activity, and NOX protein expression, leading to the amelioration of podocyte apoptosis in vitro and in vivo in patients with diabetes. This evidence concerns the gene FMO5 and diabetes mellitus.